Conivaptan

Conivaptan

File:Conivaptan structure.svg
Clinical data
Routes of administration	iv
Pharmacokinetic data
Bioavailability	N/A
Identifiers
IUPAC name N-(4-(4,5-dihydro-2-methylimidazo[4,5-d][1]benzazepin- 6(1H)-yl)carbonyl)phenyl)- (1,1'-biphenyl)-2-carboxamide
CAS Number	210101-16-9
PubChem CID	151171
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C32H26N4O2
Molar mass	498.583

WikiDoc Resources for Conivaptan
Articles
Most recent articles on Conivaptan Most cited articles on Conivaptan Review articles on Conivaptan Articles on Conivaptan in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Conivaptan Images of Conivaptan Photos of Conivaptan Podcasts & MP3s on Conivaptan Videos on Conivaptan
Evidence Based Medicine
Cochrane Collaboration on Conivaptan Bandolier on Conivaptan TRIP on Conivaptan
Clinical Trials
Ongoing Trials on Conivaptan at Clinical Trials.gov Trial results on Conivaptan Clinical Trials on Conivaptan at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Conivaptan NICE Guidance on Conivaptan NHS PRODIGY Guidance FDA on Conivaptan CDC on Conivaptan
Books
Books on Conivaptan
News
Conivaptan in the news Be alerted to news on Conivaptan News trends on Conivaptan
Commentary
Blogs on Conivaptan
Definitions
Definitions of Conivaptan
Patient Resources / Community
Patient resources on Conivaptan Discussion groups on Conivaptan Patient Handouts on Conivaptan Directions to Hospitals Treating Conivaptan Risk calculators and risk factors for Conivaptan
Healthcare Provider Resources
Symptoms of Conivaptan Causes & Risk Factors for Conivaptan Diagnostic studies for Conivaptan Treatment of Conivaptan
Continuing Medical Education (CME)
CME Programs on Conivaptan
International
Conivaptan en Espanol Conivaptan en Francais
Business
Conivaptan in the Marketplace Patents on Conivaptan
Experimental / Informatics
List of terms related to Conivaptan

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Conivaptan (vaprisol®, YM 087) is a non-peptide inhibitor of antidiuretic hormone (vasopressin). It was approved in 2004 for hyponatremia (low blood sodium levels) caused by syndrome of inappropriate antidiuretic hormone (SIADH), and there is some evidence it may be effective in heart failure. It is marketed by Astellas Pharma Inc.

Mechanism of Action

Conivaptan inhibits both isotypes of the vasopressin receptor (V1a and V2). Effectively, it causes iatrogenic nephrogenic diabetes insipidus.

See also

• Tolvaptan